Figure 1
Figure 2
Figure 3
Figure 4
Staging of testicular cancer patients and IGCCC risks classification stratified by seminoma and non-seminoma_
| Factors | Seminoma, n (%) (n = 23) | Non-seminoma, n (%)(n = 22) | Total, n (%) (n = 45) | p-value |
|---|---|---|---|---|
| Staging | 0.081 | |||
| Ib | 4 (17.4) | 1 (4.5) | 5 (11.1) | |
| IIb | 0 (0) | 1 (4.5) | 1 (2.2) | |
| IIc | 7 (30.4) | 2 (9.1) | 9 (20) | |
| IIIa | 3 (13) | 3 (13.6) | 6 (13.3) | |
| IIIb | 7 (30.4) | 6 (27.3) | 13 (28.9) | |
| IIIc | 1 (4.3) | 7 (31.8) | 8 (17.8) | |
| Is | 1 (4.3) | 2 (9.1) | 3 (6.7) | |
| IGCCC | ||||
| Good | 20 (87) | 9 (40.9) | 29 (64.4) | 0.003 |
| Intermediate | 2 (8.7) | 5 (22.7) | 7 (15.6) | |
| Poor | 1 (4.3) | 8 (36.4) | 9 (20) |
Treatment of all testicular cancer stratified by seminoma and non-seminoma_
| Treatment | Seminoma, n (%) | Non-seminoma, n (%) | Total, n (%) | p-value |
|---|---|---|---|---|
| Surveillance | 3 (13) | 2 (9.1) | 5 (11.1) | 0.451 |
| CMT | 17 (73.9) | 20 (90.9) | 37 (82.2) | |
| RT | 2 (8.7) | 0 (0) | 2 (4.4) | |
| RPLND | 1 (4.3) | 0 (0) | 1 (2.2) | |
| Chemotherapy | 0.152 | |||
| No | 6 (26.1) | 2 (9.1) | 8 (17.8) | |
| EP | 16 (69.6) | 16 (72.7) | 32 (71.1) | |
| BEP | 1 (4.3) | 4 (18.2) | 5 (11.1) | |
| Cycle | 0.234 | |||
| median(IQR) | 3 (1,4) | 4 (3,4) | 3 (2,4) |
Univariable and multivariable Cox regression analyses predicting overall survival (OS) in 45 patients with diagnosed testicular cancer between 2007 and 2016_
| Variables | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR(95%CI) | P value | HR(95%CI) | P value | |
| Classification: | ||||
| seminoma | ref | |||
| non-seminoma | 10.4 (1.32–82.21) | 0.003 | 10.2 (1.34–80.12) | 0.002 |
| T stage: | ||||
| T3–T4 vs T1–T2 | 0.67 (0.14–3.14) | 0.607 | ||
| N stage : | ||||
| N=0 | ref | |||
| N1–N2 | 0.77 (0.05–12.31) | 0.113 | ||
| N3 | 3.76 (0.47–30.1) | |||
| Serum marker | ||||
| 1 | 1.27 (0.11–14.02) | |||
| 2 | 2.15 (0.22–20.72) | 0.141 | ||
| 3 | 7.23 (0.8–64.88) | |||
| Metastasis | ||||
| no | ref | |||
| Retroperitoneal LN | 1.82 (0.21–15.63) | |||
| Lung | 0 (0- inf) | 0.625 | ||
| Bone | 0 (0- inf) | |||
| Retroperitoneal LN and lung | 3.33 (0.35–32-03) | |||
| Multiple | 2.45(0.15–39.18) | |||
| Staging | ||||
| Ib–IIIa | ref | ref | ||
| IIIb | 2.06 (0.42–10.23) | 0.006 | 2.05 (0.40–10.20) | 0.005 |
| IIIc | 6.45 (1.43–29.13) | 6.43 (1.41–29.11) | ||
| IGCCC risk classification | ||||
| good | ref | ref | ||
| Intermediate | 7.48 (1.25–44.87) | 0.003 | 7.42 (1.21–44.82) | 0.002 |
| Poor | 12.05 (2.33–62.45) | 12.01 (2.31–62.41) | ||
Tumour staging stratified by seminoma and non-seminoma_
| Variable | Seminoma, n (%) (n = 23) | Non-seminoma, n (%) (n = 22) | Total, n (%) (n-45) | p-value |
|---|---|---|---|---|
| T stage | 0.484 | |||
| 1 | 1 (4.3) | 0 (0) | 1 (2.2) | |
| 2 | 15 (65.2) | 18 (81.8) | 33 (73.3) | |
| 3 | 6 (26.1) | 4 (18.2) | 10 (22.2) | |
| 4 | 1 (4.3) | 0 (0) | 1 (2.2) | |
| N stage | 0.117 | |||
| 0 | 7 (30.4) | 3 (13.6) | 10 (22.2) | |
| 1 | 3 (13) | 4 (18.2) | 7 (15.6) | |
| 2 | 0 (0) | 4 (18.2) | 4 (8.9) | |
| 3 | 13 (56.5) | 11 (50) | 24 (53.3) | |
| M stage | 0.024 | |||
| 0 | 18 (78.3) | 9 (40.9) | 27 (60) | |
| 1 | 5 (21.7) | 13 (59.1) | 18 (40) | |
| Serum marker | 0.009 | |||
| 0 | 9 (39.1) | 1 (4.5) | 10 (22.2) | |
| 1 | 6 (26.1) | 8 (36.4) | 14 (31.1) | |
| 2 | 7 (30.4) | 6 (27.3) | 13 (28.9) | |
| 3 | 1 (4.3) | 7 (31.8) | 8 (17.8) | |
| Lymph node status | 0.284 | |||
| No | 7 (30.4) | 3 (13.6) | 10 (22.2) | |
| Metastasis | 16 (69.6) | 19 (86.4) | 35 (77.8) | |
| Pulmonary metastasis | 0.014 | |||
| No | 21 (91.3) | 12 (54.5) | 33 (73.3) | |
| Metastasis | 2 (8.7) | 10 (45.5) | 12 (26.7) | |
| Metastatic site | 0.293 | |||
| No | 4 (17.4) | 3 (13.6) | 7 (15.6) | |
| Retroperitoneal LN | 14 (60.9) | 9 (40.9) | 23 (51.1) | |
| Lung | 0 (0) | 3 (13.6) | 3 (6.7) | |
| Bone | 1 (4.3) | 0 (0) | 1 (2.2) | |
| Retroperitoneal with pulmonary | 2 (8.7) | 5 (22.7) | 7 (15.6) | |
| Multiple site | 2 (8.7) | 2 (9.1) | 4 (8.9) |
Clinical characteristics of testicular cancer testicular cancer patients_
| Variables | Seminoma (n = 23) | Non-seminoma (n = 22) | p-value |
|---|---|---|---|
| Mean age ± SD (year) | 38.1 (± 7.8) | 28.5 (± −6.9) | < 0.001 |
| Laterality of testicular mass (n (%)) | |||
| Right | 10 (43.5) | 9 (40.9) | |
| Left | 12 (52.2) | 12 (54.5) | |
| Both | 1 (4.3) | 1 (4.5) | |
| Pre-op tumour markers (median, ng/mL) | |||
| AFP (IQR) | 2.4 (2–3.8) | 944 (116.2–1,992.2) | < 0.001 |
| bHCG (IQR) | 12 (3.5–34.3) | 120.3 (11.2–3,588.5) | 0.005 |
| LDH (IQR) | 545 (333–1,137.5) | 500 (349.5–946.5) | 0.716 |
| Post orchiectomy (median, ng/mL) | |||
| AFP (IQR) | 2.7 (2–3.6) | 70 (3–1,609.8) | 0.012 |
| BHCG (IQR) | 2.2 (1–9.2) | 10.9 (1.1–323.6) | 0.099 |
| LDH (IQR) | 373 (323.5–734) | 438 (327.5–650.5) | 0.892 |